BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 6339042)

  • 1. Biochemical effects and therapeutic potential of tunicamycin in murine L1210 leukemia.
    Morin MJ; Bernacki RJ
    Cancer Res; 1983 Apr; 43(4):1669-74. PubMed ID: 6339042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biochemical and ultrastructural effects of tunicamycin and D-glucosamine in L1210 leukemic cells.
    Morin MJ; Porter CW; McKernan P; Bernacki RJ
    J Cell Physiol; 1983 Feb; 114(2):162-72. PubMed ID: 6822608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic and diabetogenic potential of two newly synthesized nitrosoureido sugars.
    Bernacki RJ; Wilson GL; Mossman BT; Angelino N; Kanter PM; Korytnyk W
    Cancer Res; 1985 Feb; 45(2):695-702. PubMed ID: 3881170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell surface alterations associated with exposure of leukemia L1210 cells to fluorouracil.
    Kessel D
    Cancer Res; 1980 Feb; 40(2):322-4. PubMed ID: 7356515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells.
    Barrueco JR; Jacobsen DM; Chang CH; Brockman RW; Sirotnak FM
    Cancer Res; 1987 Feb; 47(3):700-6. PubMed ID: 3802076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models.
    Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
    Cancer Res; 1976 Dec; 36(12):4672-8. PubMed ID: 1000510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide.
    Skórski T; Kawalec M
    Exp Hematol; 1988 Oct; 16(9):782-4. PubMed ID: 3049130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.
    Cass CE; Au-Yeung TH
    Cancer Res; 1976 Apr; 36(4):1486-91. PubMed ID: 944095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of selenium on the growth of L1210 leukemic cells.
    Milner JA; Hsu CY
    Cancer Res; 1981 May; 41(5):1652-6. PubMed ID: 7214335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake, initial effects, and chemotherapeutic efficacy of harringtonine in murine leukemic cells sensitive and resistant to vincristine and other chemotherapeutic agents.
    Chou TC; Schmid FA; Feinberg A; Philips FS; Han J
    Cancer Res; 1983 Jul; 43(7):3074-9. PubMed ID: 6189591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of novel octalactin A analogs in murine leukemia cells in vitro.
    Perchellet JP; Perchellet EM; Newell SW; Freeman JA; Ladesich JB; Jeong Y; Sato N; Buszek K
    Anticancer Res; 1998; 18(1A):97-106. PubMed ID: 9568062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological characterization of a prolonged antileukemic effect of 5-azacytidine.
    Presant CA; Valeriote F; Vietti TJ
    Cancer Res; 1977 Feb; 37(2):376-81. PubMed ID: 64294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of DNA synthesis and enhancement of the uptake and action of methotrexate by low-power-density microwave radiation in L1210 leukemia cells.
    Chang BK; Huang AT; Joines WT
    Cancer Res; 1980 Apr; 40(4):1002-5. PubMed ID: 7357530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo antitumor activity of the bitter melon (Momordica charantia).
    Jilka C; Strifler B; Fortner GW; Hays EF; Takemoto DJ
    Cancer Res; 1983 Nov; 43(11):5151-5. PubMed ID: 6616452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curative effect of DL-2-difluoromethylornithine on mice bearing mutant L1210 leukemia cells deficient in polyamine uptake.
    Persson L; Holm I; Ask A; Heby O
    Cancer Res; 1988 Sep; 48(17):4807-11. PubMed ID: 3136913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of in vivo and in vitro effects of continuous exposure of L1210 cells to 6-thioguanine.
    Maybaum J; Morgans CW; Hink LA
    Cancer Res; 1987 Jun; 47(12):3083-7. PubMed ID: 3581060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tunicamycin on B16 metastatic melanoma cell surface glycoproteins and blood-borne arrest and survival properties.
    Irimura T; Gonzalez R; Nicolson GL
    Cancer Res; 1981 Sep; 41(9 Pt 1):3411-8. PubMed ID: 7260906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of L-canavanine against L1210 murine leukemia.
    Green MH; Brooks TL; Mendelsohn J; Howell SB
    Cancer Res; 1980 Mar; 40(3):535-7. PubMed ID: 7471074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of in vitro and in vivo effects of thymidine on L1210 leukemia in mice.
    Zaharko DS; Ramonas LM
    J Natl Cancer Inst; 1982 May; 68(5):875-80. PubMed ID: 6951095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.